



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

## Journal Pre-proof

WITHDRAWN: Common NLRP3 inflammasome inhibitors and Covid-19: Divide and Conquer



Gaber El-Saber Batiha , Dr. Ali I. Al-Gareeb , Safaa Qusti ,  
Eida M. Alshammari , Damilare Rotimi ,  
Oluyomi Stephen Adeyemi , Hayder M. Al-kuraishy

PII: S2468-2276(21)00385-9  
DOI: <https://doi.org/10.1016/j.sciaf.2021.e01084>  
Reference: SCIAF 1084

To appear in: *Scientific African*

Received date: 12 August 2021  
Revised date: 2 December 2021  
Accepted date: 16 December 2021

Please cite this article as: Gaber El-Saber Batiha , Dr. Ali I. Al-Gareeb , Safaa Qusti , Eida M. Alshammari , Damilare Rotimi , Oluyomi Stephen Adeyemi , Hayder M. Al-kuraishy , WITHDRAWN: Common NLRP3 inflammasome inhibitors and Covid-19: Divide and Conquer, *Scientific African* (2021), doi: <https://doi.org/10.1016/j.sciaf.2021.e01084>

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2021 Published by Elsevier B.V. on behalf of African Institute of Mathematical Sciences / Next Einstein Initiative.

This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>)

WITHDRAWN: **Common NLRP3 inflammasome inhibitors and Covid-19: Divide and Conquer**

Gaber El-Saber Batiha<sup>1</sup> gaberbatiha@gmail.com, Ali I. Al-Gareeb<sup>2</sup> Dr.alialgareeb78@yahoo.com; Hayderm36@yahoo.com, Safaa Qusti<sup>3</sup> squsti@kau.edu.sa, Eida M. Alshammari<sup>4</sup> eida.alshammari@uoh.edu.sa, Damilare Rotimi<sup>5,\*</sup> rotimi.damilare@lmu.edu.ng, Oluyomi Stephen Adeyemi<sup>5</sup> yomibowa@yahoo.com, Hayder M. Al-kuraishy<sup>2</sup>

<sup>1</sup>Department of Pharmacology and Therapeutics, Faculty of Veterinary Medicine, Damanhour University, Damanhour 22511, AlBeheira, Egypt

<sup>2</sup>Department of Clinical Pharmacology and Medicine, College of Medicine, AlMustansiriya University, Baghdad, Iraq

<sup>3</sup>Biochemistry Department, Faculty of Science, King Abdulaziz University, Jeddah, Saudi Arabia

<sup>4</sup>Department of Chemistry, College of Sciences, University of Ha'il, Ha'il, Saudi Arabia

<sup>5</sup>Department of Biochemistry, Landmark University, KM 4 Ipetu Road, Omu-Aran 251101, Kwara State, Nigeria

This article has been withdrawn at the request of the author(s) and/or editor. The Publisher apologizes for any inconvenience this may cause.

The full Elsevier Policy on Article Withdrawal can be found at <https://www.elsevier.com/about/our-business/policies/article-withdrawal>

---

\* Corresponding author: Landmark University, Nigeria